Rob Sahr Quoted by IPWatchdog on Allergan Decision
2 min read
Rob Sahr was quoted by IPWatchdog in an article titled “CAFC Says ‘First-Filed, First-Issued, Later Expiring Claim’ is Not Invalid for ODP.” This article covers how the Allergan v. MSN Labs. decision is the first exception to the obviousness-type double patenting (ODP) scenarios decided in In re Cellect. Rob discusses how the Federal Circuit has spared many pharmaceutical patents that have both patent term adjustment (PTA) and patent term extension (PTE) that might otherwise have been doomed by ODP and left with a valid PTE period but invalid claims. Read more.
Related content:
- Allergan ‘First’ Exception to Cellect ODP Scenarios
- Scott McKeown Quoted by Law360 on Allergan Decision
- In re Cellect: What In-House Counsel Needs to be Doing Right Now
- Rob Sahr Quoted by IPWatchdog on In re Cellect
- Wolf Greenfield Webinar: Avoiding the “Cellect-ion” of your Patent Portfolio: What You Need to Know Now About PTA & PTE in the New Double Patenting Environment